论文部分内容阅读
目的:评价艾迪注射液协同多西他赛联合顺铂(DP)方案化疗对女性晚期非小细胞肺癌(NSCLC)患者的疗效、免疫功能和生活质量的影响。方法:回顾性分析79例晚期女性NSCLC患者,按照治疗情况分为治疗组41例和对照组38例。治疗组采用艾迪注射液联合DP方案化疗,对照组单用DP方案化疗。21 d为1个周期,2个周期后进行评价。结果:治疗组有效率51.2%,对照组39.5%;治疗组疾病控制率82.1%,对照组66.7%,治疗组优于对照组(P<0.05)。治疗组治疗后CD_3~+,CD_4~+,CD_4~+/CD_8~+较治疗前及对照组治疗后增加,CD_8~+降低(P<0.05,P<0.01)。治疗组治疗后生理状况、社会和家庭状况及总量表分值较治疗前及对照组治疗后提高(P<0.05,P<0.01)。毒副反应集中体现在骨髓抑制和胃肠道反应两方面;其中,治疗组Ⅲ/Ⅳ度白细胞减少及血红蛋白减少低于对照组(P<0.05,P<0.01)。结论:艾迪注射液联合DP方案可以提高女性MSCLC患者的疗效、细胞免疫功能状态、生活质量情况,且降低毒副反应,值得临床推广应用。
Objective: To evaluate the effect of Aidi Injection in combination with docetaxel plus cisplatin (DP) regimen on the efficacy, immune function and quality of life in female patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 79 patients with advanced NSCLC were retrospectively analyzed. According to the treatment, they were divided into treatment group (41 cases) and control group (38 cases). The treatment group with Aidi injection combined with DP chemotherapy, the control group with DP chemotherapy alone. 21 d for a period of 2 weeks after the evaluation. Results: The effective rate was 51.2% in the treatment group and 39.5% in the control group. The disease control rate in the treatment group was 82.1% and that in the control group was 66.7%. The treatment group was superior to the control group (P <0.05). After treatment, CD_3 ~ +, CD_4 ~ + and CD_4 ~ + / CD_8 ~ + in the treatment group were increased and CD_8 ~ + decreased (P <0.05, P <0.01). Physiological status, social and family status and total scale score of treatment group after treatment were higher than those before treatment and control group after treatment (P <0.05, P <0.01). Toxic side effects concentrated in the two aspects of myelosuppression and gastrointestinal reactions; the treatment group Ⅲ / Ⅳ leukopenia and hemoglobin decreased less than the control group (P <0.05, P <0.01). Conclusion: Aidi injection combined with DP regimen can improve the efficacy, cellular immune function and quality of life in female patients with MScLCLC, and reduce the side effects. It is worthy of clinical application.